目的 分析辽宁省肿瘤医院抗肿瘤辅助用药的应用情况，为临床合理用药提供参考。方法 对2014-2016年辽宁省肿瘤医院抗肿瘤辅助用药的销售金额、用药频度（DDDs）、限定日费用（DDC）等进行统计分析。结果 2014-2016年抗肿瘤辅助用药的销售金额逐年增加；中成药销售金额连续3年均排在第1位；康艾注射液的销售金额逐年增加，排序均居第1位；注射用泮托拉唑钠的DDDs始终排在第1位；各个药品的DDC值相对较稳定，DDC较高的有康艾注射液、舒肝宁注射液和注射用核糖核酸Ⅱ。结论 2014-2016年辽宁省肿瘤医院抗肿瘤辅助用药的应用总体上合理，但仍需加强监督管理，规范辅助用药使用行为。

Objective To analyze the usage of anti-tumor adjuvant drugs, and to provide reference for rational use of anti-tumor adjuvant drugs. Methods Consumption sum, defined daily doses (DDDs), and defined daily cost (DDC) of anti-tumor adjuvant drugs in Liaoning Cancer Hospital and Institute from 2014 to 2016 were analyzed statistically. Results From 2014 to 2016, the total consumption sums of anti-tumor adjuvant drugs were increasing year by year. Consumption sums of Chinese traditional patent medicine ranked the first for three years. The sales amount of Kang'ai Injection increased year by year, and always ranked the first. DDDs of Pantoprazole for injection ranked the first for three years. DDC values of anti-tumor adjuvant drugs were relatively stable. DDC of Kang'ai Injection, Shuganning Injection, and Ribonucleic acid Ⅱ for injection were higher. Conclusion The application of anti-tumor adjuvant drugs in Liaoning Cancer Hospital and Institute from 2014 to 2016 is rational on the whole, meanwhile, supervision should be strengthened to standardize medication behavior.